Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET

Company Participants

Lisa Miller - Senior Director of Investor Relations

Richard Hawkins - Chairman and Chief Executive Officer

Lori Lawley - Chief Financial Officer

John McKew - President and Chief Scientific Officer

David Karpf - Chief Medical Officer

Conference Call Participants

Charles Duncan - Cantor Fitzgerald, L.P

Emma Nesson - Piper Sandler & Co.

Edward White - H.C. Wainwright & Co, LLC

Catherine Novack - Jones Research

Leland Gershell - Oppenheimer & Co. Inc.

Elemer Piros - ROTH Capital Partners

Operator

Good afternoon, and welcome to Lumos Pharma's Second Quarter 2022 Results and Clinical Update Conference Call. Currently, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded.

I'd now turn the call over to Lisa Miller, Senior Director of Investor Relations.

Lisa Miller

Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release we issued this afternoon and in our Form 8-K, which may be accessed from the Investors page of the Company's website.

Speaking on today's call will be Rick Hawkins, CEO and Chairman; John McKew, our President and Chief Scientific Officer; Dr. David Karpf, our Chief Medical Officer; and Lori Lawley, our Chief Financial Officer.

I will now turn the call over to Rick.

Richard Hawkins

Thank you, Lisa, and good afternoon, everyone, and thank you for joining us on today's call. So after the market closed today, we issued a press release announcing our financial results for the 2022 second quarter and detailing our progress advancing our clinical program evaluating LUM-201 for the treatment of idiopathic or moderate pediatric growth hormone deficiency or PGHD.

On today's call, I'll provide a brief update on LUM-201 clinical trials and other developments before turning it over to Lori Lawley for a review of our financial results. Then John and David will join us for our Q&A session.